Trials / Terminated
TerminatedNCT00737360
Phase II Study of TAS-106 to Treat Head and Neck Cancer
Phase II Study of TAS-106 in Patients With Recurrent or Metastatic Head and Neck Cancer Refractory to Platinum Based Chemotherapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Taiho Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether TAS-106 is effective to patients with recurrent or metastatic head and neck cancer refractory to platinum based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAS-106 | 6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops. |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2011-06-01
- Completion
- 2012-02-01
- First posted
- 2008-08-19
- Last updated
- 2012-09-05
- Results posted
- 2012-09-05
Locations
5 sites across 4 countries: United States, Hong Kong, Singapore, Taiwan
Source: ClinicalTrials.gov record NCT00737360. Inclusion in this directory is not an endorsement.